Form 4: MAIA Biotechnology Executive Granted Stock Options

Sergei Gryaznov, Chief Scientific Officer of MAIA Biotechnology, Inc., was granted stock options for 200,000 shares on May 14, 2025.

Summary

• Sergei Gryaznov, the Chief Scientific Officer of MAIA Biotechnology, Inc., filed a Form 4 on May 15, 2025.
• The filing reports a transaction that occurred on May 14, 2025, where Gryaznov was granted stock options.
• He received options for 200,000 shares of MAIA Biotechnology's common stock at an exercise price of $1.76 per share.
• The options vest over a 4-year period, with 25% vesting on the first anniversary and the remaining options vesting monthly over the subsequent 36 months.
• Following the transaction, Gryaznov directly owns derivative securities for 200,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed favorably as it aligns executive interests with shareholder value. There are no immediate negative implications.

Positives

• The granting of stock options to the Chief Scientific Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with the long-term success of the company. This is a standard method for attracting and retaining talent, especially in high-growth sectors.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their leadership teams.
• The vesting schedule of 4 years with a 1-year cliff is also a common practice to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Scientific Officer to drive company growth.
• Employees may see this as a positive sign of investment in the leadership team.

Key Dates

Keywords

MAIA Biotechnology, Stock Options, Form 4, Sergei Gryaznov, Equity Incentive Plan, Beneficial Ownership